Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAX2012Q
- Development stage
- Phase 2
- Lead developer
- VaxInnate
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
VAX2012Q is a quadrivalent seasonal influenza vaccine candidate developed by VaxInnate. It consists of four hemagglutinin subunits (H1N1, H3N2, B-Yamagata, and B-Victoria) genetically fused to flagellin, a bacterial protein that acts as a Toll-like receptor 5 (TLR5) agonist. This fusion enhances the immune response by activating both innate and adaptive immunity. The vaccine is produced using recombinant DNA technology, allowing for rapid and scalable manufacturing. Clinical studies in healthy adults have shown that VAX2012Q elicits robust immune responses at various dose levels with high seroprotection rates and an acceptable safety profile characterized mainly by mild to moderate injection site pain[1][2][3][7].
02
Targets
TLR5HA (Hemagglutinin)
Beyond the preview
Go deeper on VAX2012Q.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAX2012Q.